Search Result

Results for "

liver failure

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (1) Biochemical Assay Reagents (4) Caspase (1) CCR (2) CMV (1) Endogenous Metabolite (2) GABA Receptor (2) Glutathione Peroxidase (1) Hedgehog (1) HIV (1) HSV (1) Influenza Virus (1) Isotope-Labeled Compounds (1) JNK (1) MDM-2/p53 (1) NF-κB (1) NKCC (2) NOD-like Receptor (NLR) (1) p38 MAPK (1) Phosphodiesterase (PDE) (1) YB-1 (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (7) Endocrinology (2) Infection (1) Inflammation/Immunology (4) Metabolic Disease (9)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124899

Hh-Ag1.5 1 Publications Verification SAg1.5	Hedgehog	Metabolic Disease
Hh-Ag1.5 (SAg1.5) is a potent Hedgehog (Hh) agonist with an EC₅₀ of 1 nM . Hh-Ag1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure .

HY-42682

D(+)-Galactosamine hydrochloride 1 Publications Verification D-Galactosamine HCl	Others	Inflammation/Immunology
D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

HY-N1131

Triacetonamine 1 Publications Verification 2,2,6,6-Tetramethyl-4-piperidone	Biochemical Assay Reagents	Metabolic Disease
Triacetonamine (2,2,6,6-Tetramethyl-4-piperidone) is used as an intermediate for the synthesis of pharmaceutical products, pesticides and photostabilizers for polymers. Triacetonamine has oral activity and can induce acute liver failure (ALF) in rats .

HY-152860

Darizmetinib HRX-0215	p38 MAPK JNK NF-κB MDM-2/p53	Cancer
Darizmetinib (HRX-0215) is an orally active, potent and selective inhibitor of mitogen-activated protein kinase kinase 4 (MKK4). Darizmetinib leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Darizmetinib is promising for research of preventing liver failure after extensive oncological liver resections or transplantation of small liver grafts .

HY-129982

SC-435	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .

HY-142059

PDE5-IN-4	Phosphodiesterase (PDE)	Cardiovascular Disease Metabolic Disease
PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure .

HY-42682R

D(+)-Galactosamine (hydrochloride) (Standard)	Others	Inflammation/Immunology
D(+)-Galactosamine (hydrochloride) (Standard) is the analytical standard of D(+)-Galactosamine (hydrochloride). This product is intended for research and analytical applications. D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

HY-N1131B

Triacetonamine monohydrate 2,2,6,6-Tetramethyl-4-piperidone monohydrate	Biochemical Assay Reagents	Metabolic Disease
Triacetonamine (2,2,6,6-Tetramethyl-4-piperidone) monohydrate is used as an intermediate for the synthesis of pharmaceutical products, pesticides and photostabilizers for polymers. Triacetonamine hydrochloride has oral activity and can induce acute liver failure (ALF) in rats .

HY-N1131A

Triacetonamine hydrochloride 2,2,6,6-Tetramethyl-4-piperidone hydrochloride	Biochemical Assay Reagents	Metabolic Disease
Triacetonamine (2,2,6,6-Tetramethyl-4-piperidone) hydrochloride is used as an intermediate for the synthesis of pharmaceutical products, pesticides and photostabilizers for polymers. Triacetonamine hydrochloride has oral activity and can induce acute liver failure (ALF) in rats .

HY-113963

Ac-IETD-CHO	Apoptosis	Cancer
Ac- IETD- CHO is a potent, reversible inhibitor of granzyme B and caspase-8. Ac- IETD- CHO inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac- IETD- CHO also inhibits cytotoxic T lymphocytes induced cell death .

HY-W013411A

Locostatin UIC-1005	Others	Cancer
Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .

HY-15450A

INCB 3284 2 Publications Verification	CCR	Endocrinology
INCB 3284 is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC₅₀ of 3.7 nM. INCB 3284 can be used in the research of acute liver failure.

HY-A0282

L-Ornithine L-aspartate	Others	Metabolic Disease Inflammation/Immunology
L-Ornithine L-aspartate is a stable salt of two natural nonessential L-amino acids with oral activity: ornithine and aspartic acid. L-Ornithine L-aspartate lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis. L-Ornithine L-aspartate also improves mitochondrial functions .

HY-15450

INCB 3284 dimesylate	CCR	Endocrinology
INCB 3284 dimesylate is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC₅₀ of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.

HY-N1131S

Triacetonamine-d17 2,2,6,6-Tetramethyl-4-piperidone-d₁₇	Biochemical Assay Reagents Isotope-Labeled Compounds	Others
Triacetonamine-d17 (2,2,6,6-Tetramethyl-4-piperidone-d17) is the deuterium labeled Triacetonamine. Triacetonamine has oral activity and can induce acute liver failure (ALF) in rats .

HY-145581

Mitiperstat AZD4831	Glutathione Peroxidase	Cardiovascular Disease
Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease .

HY-122920

Soyasaponin II	HSV CMV Influenza Virus HIV NOD-like Receptor (NLR) YB-1	Infection Inflammation/Immunology
Soyasaponin II is a saponin with antiviral activity. Soyasaponin II inhibits the replication of HSV-1, HCMV, influenza virus, and HIV-1. Soyasaponin II shows potent inhibition on HSV-1 replication. Soyasaponin II serves as a inhibitor for YB-1 phosphorylation and NLRP3 inflammasome priming and could protect mice against LPS/GalN induced acute liver failure .

HY-167681

Carprazidil Ro 12-4713	Others	Cardiovascular Disease
Carprazidil (Ro 12-4713) is a potent vasodilator with activity in suppressing severe hypertension and mild heart failure. The use of carprazidil may lead to sodium retention and increased heart rate, requiring increased doses of diuretics or beta-blockers in some cases. Carprazidil and mecycline may both cause hirsutism, limiting their long-term use in women. Carprazidil did not cause adverse side effects on hematological parameters, liver, or kidney function .

HY-W013411

(E/Z)-Locostatin (E/Z)-UIC-1005	Others	Cancer
(E/Z)-Locostatin ((E/Z)-UIC-1005) is a racemic of Locostatin. Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .

HY-B0135

Furosemide 2 Publications Verification	NKCC GABA Receptor	Cardiovascular Disease Metabolic Disease Cancer
Furosemide is a potent and orally active inhibitor of Na ⁺/K ⁺/2Cl ^-?(NKCC) cotransporter, NKCC1 and NKCC2 .?Furosemide is also a GABA_A?receptors antagonist and displays 100-fold selectivity for?α6-containing receptors than?α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .

HY-B0135A

Furosemide sodium 2 Publications Verification	NKCC GABA Receptor	Cardiovascular Disease Metabolic Disease Cancer
Furosemide sodium is a potent and orally active inhibitor of Na ⁺/K ⁺/2Cl ^- (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide sodium is also a GABA_A receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .

HY-10397A

MX1013 2 Publications Verification CV1013; Z-VD-FMK	Caspase	Cancer
MX1013 is a potent, irreversible dipeptide caspase inhibitor vith antiapoptotic activity. MX1013 inhibits recombinant human caspase 3 with an IC₅₀ of 30 nM .

HY-155156

PF-07238025	Endogenous Metabolite	Cardiovascular Disease
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-155157

PF-07247685	Endogenous Metabolite	Cardiovascular Disease
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

Cat. No.	Product Name

HY-L185

Anti-Fibrosis Compound Library	1,753 compounds
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 1,753 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Anti-Fibrosis Compound Library

1,753 compounds

Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.

MCE contains 1,753 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

HY-L087

Anti-Obesity Compound Library	2,618 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 2,618 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

2,618 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2,618 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Target	Research Area